Exploring ID4 as a driver of aggression and a therapeutic target in triple-negative breast cancer
Abstract Basal-like breast cancer (BLBC) is an aggressive subtype with poor prognosis and limited treatment options. The Inhibitor of Differentiation 4 (ID4) protein is frequently overexpressed in BLBC, yet its role in tumor progression remains unclear. Here, we used CRISPR–Cas9-mediated ID4 knockou...
Saved in:
| Main Authors: | C. Toro, S. Real, S. Laurito, M. T. Branham |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00787-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the therapeutic potential and in vitro validation of baicalin for the treatment of triple-negative breast cancer
by: Yuan Ma, et al.
Published: (2025-04-01) -
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review
by: Lucía Serrano García, et al.
Published: (2024-12-01) -
LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a therapeutic target
by: Qiqi Xue, et al.
Published: (2025-03-01) -
Stromal PLAU mediates tumor progression and informs a novel therapeutic target in triple-negative breast cancer
by: Jun Zou, et al.
Published: (2025-07-01) -
Targeting a cell state common to triple‐negative breast cancers
by: Markus K Muellner, et al.
Published: (2015-02-01)